Krsnaa DiagnosticsNSE:KRSNAA +0.13%71 EBITDA Margin % is 44.84% as of Mar. 2026, which is 52% above its 10-year median of 29.45. GuruFocus rates NSE:KRSNAA with a GF Score™ of 71/100 and a GF Value™ of ₹898.08 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Krsnaa Diagnostics ranks better than 93.6% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Krsnaa Diagnostics's EBITDA for the
three
months ended in Mar. 2026 was ₹864 Mil. Krsnaa Diagnostics's Revenue for the
three
months ended in Mar. 2026 was ₹1,926 Mil. Therefore, Krsnaa Diagnostics's EBITDA margin for the quarter that ended in Mar. 2026 was 44.84%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Krsnaa Diagnostics EBITDA Margin % Related Terms
Krsnaa Diagnostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Krsnaa Diagnostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:KRSNAA vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Krsnaa Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krsnaa Diagnostics EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Krsnaa Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Krsnaa Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krsnaa Diagnostics (NSE:KRSNAA) has a EBITDA Margin % of 44.84% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krsnaa Diagnostics and its competitors. This is 52% above median its historical median of 29.45. According to the industry distribution chart, Krsnaa Diagnostics ranks #13 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 6.4%.
Is Krsnaa Diagnostics' EBITDA Margin % too high?
Krsnaa Diagnostics' current EBITDA Margin % of 44.84% is 52% above median its 10-year median of 29.45. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Krsnaa Diagnostics' value of 44.84% is 796.8% above this industry median. Based on the distribution chart, Krsnaa Diagnostics ranks #13 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Krsnaa Diagnostics has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Krsnaa Diagnostics' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Krsnaa Diagnostics ranks #13 out of 203 companies for EBITDA Margin %. This places Krsnaa Diagnostics in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Krsnaa Diagnostics' value of 44.84% is 796.8% above this benchmark. While the company's 10-year median is 29.45 vs. the industry median of 5.00, Krsnaa Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krsnaa Diagnostics's current EBITDA Margin % of 44.84% is 796.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krsnaa Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krsnaa Diagnostics's current EBITDA Margin % is 44.84%, which is 52% above median its own 10-year median of 29.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krsnaa Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Krsnaa Diagnostics (NSE:KRSNAA) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹898.08, compared to a current price of ₹538.25 — trading 40.1% below its estimated fair value. The current EBITDA Margin % is 44.84%, which is 52% above median its 10-year median of 29.45 and 796.8% above the Medical Diagnostics & Research industry median of 5.00. Krsnaa Diagnostics' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Krsnaa Diagnostics (NSE:KRSNAA), the current EBITDA Margin % is 44.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krsnaa Diagnostics (NSE:KRSNAA) Overvalued in 2026?
Based on GuruFocus' analysis, Krsnaa Diagnostics stock appears to be undervalued.
The current stock price of ₹538.25 is trading 40.1% below its estimated GF Value™ of ₹898.08.
GuruFocus considers Krsnaa Diagnostics to be Significantly Undervalued.
Key valuation signals for NSE:KRSNAA:
EBITDA Margin %: 44.84% (52% above median its 10-year median of 29.45)
GF Value™: ₹898.08 vs. price of ₹538.25 (40.1% below fair value)
Industry Position: 796.8% above the Medical Diagnostics & Research median (#13 of 203)
No single metric tells the full story. See the NSE:KRSNAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krsnaa Diagnostics Ltd is a diagnostic services provider, both in Radiology and Pathology. It offers a wide range of diagnostic services such as imaging/radiology services, routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres. The company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, tele-reporting services, and all types of Blood and Urine investigations.
71GF Score
Get the complete analysis for NSE:KRSNAA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KRSNAA has been successfully added to your 
